4.7 Review

Early diagnosis of acute coronary syndrome

期刊

EUROPEAN HEART JOURNAL
卷 38, 期 41, 页码 3049-+

出版社

OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehx492

关键词

Acute coronary syndrome; Troponin

资金

  1. Abbott Vascular
  2. Abbott
  3. Abbott Diagnostics
  4. Bayer
  5. Boehringer Ingelheim
  6. Thermo Fisher
  7. Siemens
  8. Medtronic
  9. Pfizer
  10. Roche
  11. Siemens Diagnostics
  12. Novartis
  13. Phillips Healthcare Incubator
  14. AstraZeneca
  15. Biotronik
  16. BMS
  17. Daiichi Sankyo
  18. Sanofi
  19. Philips
  20. MicroPort
  21. Bayer/Janssen
  22. Sanofi/Regeneron
  23. Thermofisher
  24. BioMerieux
  25. GlaxoSmithKline
  26. Roche Diagnostics
  27. Singulex
  28. Brahms ThermoFisher
  29. Bayer Healthcare
  30. European Society of Cardiology
  31. Heart Failure Association of the European Society of Cardiology
  32. Heart Failure Society of America
  33. Cardiovascular Clinical Trialists (CVCT) and Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists (INI-CRCT)
  34. Celyad
  35. Respicardia
  36. Heart Flow, Inc.
  37. Milestone Pharmaceuticals
  38. Sanofi-Aventis

向作者/读者索取更多资源

The diagnostic evaluation of acute chest pain has been augmented in recent years by advances in the sensitivity and precision of cardiac troponin assays, new biomarkers, improvements in imaging modalities, and release of new clinical decision algorithms. This progress has enabled physicians to diagnose or rule-out acute myocardial infarction earlier after the initial patient presentation, usually in emergency department settings, which may facilitate prompt initiation of evidence-based treatments, investigation of alternative diagnoses for chest pain, or discharge, and permit better utilization of healthcare resources. A non-trivial proportion of patients fall in an indeterminate category according to rule-out algorithms, and minimal evidence-based guidance exists for the optimal evaluation, monitoring, and treatment of these patients. The Cardiovascular Round Table of the ESC proposes approaches for the optimal application of early strategies in clinical practice to improve patient care following the review of recent advances in the early diagnosis of acute coronary syndrome. The following specific 'indeterminate' patient categories were considered: (i) patients with symptoms and high-sensitivity cardiac troponin <99th percentile; (ii) patients with symptoms and high-sensitivity troponin <99th percentile but above the limit of detection; (iii) patients with symptoms and high-sensitivity troponin >99th percentile but without dynamic change; and (iv) patients with symptoms and high-sensitivity troponin >99th percentile and dynamic change but without coronary plaque rupture/erosion/dissection. Definitive evidence is currently lacking to manage these patients whose early diagnosis is 'indeterminate' and these areas of uncertainty should be assigned a high priority for research.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据